Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 25 of 42 entries
View as:

Treatment of Impulsive Aggression in Subjects With ADHD in Conjunction With Standard ADHD Treatment (CHIME 2)

Phase: N/A Priority: Normal
NCT ID: NCT02618434 Org: User:
Start: 02/16/16 End: 02/14/20 Due: 02/14/21

Functional MRI Study in Healthy Children Engaged in Aggressive Behaviors

Phase: N/A Priority: Normal
NCT ID: NCT03615703 Org: User:
Start: 08/10/18 End: 03/15/19 Due: 03/15/20

A Study to Evaluate the Efficacy and Safety of SPN-810 as Adjunctive Therapy in Children With Impulsive Aggression Comorbid With Attention-Deficit/Hyperactivity Disorder (ADHD)

Phase: N/A Priority: Normal
NCT ID: NCT01364662 Org: User:
Start: 06/30/11 End: 10/31/12 Due: 10/31/13

Clinical Outcome Assessment of Parkinson's Disease Patients Treated With XADAGO (Safinamide)

Phase: N/A Priority: Normal
NCT ID: NCT03944785 Org: User:
Start: 11/30/17 End: 01/10/20 Due: 01/10/21

Therapy for Migraine Prevention in Children 6-11 Years of Age

Phase: N/A Priority: Normal
NCT ID: NCT04050293 Org: User:
Start: 07/14/20 End: 05/29/24 Due: 05/29/25

Phase 2a Study of Safety and Tolerability of SPN-810 in Children With ADHD and Persistent Serious Conduct Problems

Phase: N/A Priority: Normal
NCT ID: NCT00626236 Org: User:
Start: 09/30/08 End: 10/31/09 Due: 10/31/10

Study of PK and Safety of OXC (Oxcarbazepine) XR (Extended Release) as Adjunctive Therapy in Pediatric Epilepsy Patients

Phase: N/A Priority: Normal
NCT ID: NCT00918047 Org: User:
Start: 06/30/09 End: 11/30/10 Due: 11/30/11

Open-Label, Extension Study to 810P202

Phase: N/A Priority: Normal
NCT ID: NCT01416064 Org: User:
Start: 09/30/11 End: 02/28/13 Due: 02/28/14

Mass Balance Study of NV-5138 in Healthy Male Subjects

Phase: N/A Priority: Normal
NCT ID: NCT05384977 Org: User:
Start: 11/11/21 End: 12/09/21 Due: 12/09/22

Efficacy and Safety of SPN-812 (Viloxazine Extended-release Capsule) in Children With ADHD

Phase: N/A Priority: Normal
NCT ID: NCT02633527 Org: User:
Start: 02/01/16 End: 07/25/16 Due: 07/25/17

A Conversion Study of Immediate Release (IR) and Modified Release (MR) Forms of Topiramate (TPM)

Phase: N/A Priority: Normal
NCT ID: NCT01114854 Org: User:
Start: 06/30/10 End: 01/31/11 Due: 01/31/12

Evaluation of SPN-812 (Viloxazine Extended-release Capsule) High Dose in Adolescents With ADHD

Phase: N/A Priority: Normal
NCT ID: NCT03247556 Org: User:
Start: 11/20/17 End: 02/14/19 Due: 02/14/20

Phase I Study to Assess the Absorption, Metabolism, and Excretion of [14C] Labeled SPN-810M

Phase: N/A Priority: Normal
NCT ID: NCT02023606 Org: User:
Start: 11/30/13 End: 12/31/13 Due: 12/31/14

Evaluation of Viloxazine and Its Metabolite 5-Hydroxy-viloxazine Glucuronide Into Breast Milk in Healthy Lactating Women

Phase: N/A Priority: Normal
NCT ID: NCT06259331 Org: User:
Start: 05/23/23 End: 09/20/23 Due: 09/20/24

Bioavailability, Safety, and Tolerability of BIS-001 ER

Phase: N/A Priority: Normal
NCT ID: NCT03156439 Org: User:
Start: 05/22/17 End: 09/30/17 Due: 09/30/18

BIS-001-ER for the Treatment of Adult Focal Impaired Awareness Seizures

Phase: N/A Priority: Normal
NCT ID: NCT03474770 Org: User:
Start: 04/10/18 End: 12/30/26 Due: 12/30/27

Evaluation of the Pharmacokinetics, Safety, and Tolerability of TPM XR as Adjunctive Therapy in Pediatric Subjects With Epilepsy

Phase: N/A Priority: Normal
NCT ID: NCT01284530 Org: User:
Start: 01/31/11 End: 06/30/12 Due: 06/30/13

Open-label Study to Evaluate Long-term Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule)

Phase: N/A Priority: Normal
NCT ID: NCT02736656 Org: User:
Start: 02/02/16 End: 09/30/26 Due: 09/30/27

Open-Label Study of SPN-812 Administered With Psychostimulants in Children and Adolescents With ADHD

Phase: N/A Priority: Normal
NCT ID: NCT04786990 Org: User:
Start: 07/27/21 End: 07/26/23 Due: 07/26/24

Efficacy and Safety Study of MYOBLOC® in the Treatment of Adult Lower Limb Spasticity

Phase: N/A Priority: Normal
NCT ID: NCT04099667 Org: User:
Start: 12/17/19 End: 07/31/24 Due: 07/31/25

Safety and Tolerability of OXC XR as Adjunctive Therapy in Subjects With Refractory Partial Epilepsy

Phase: N/A Priority: Normal
NCT ID: NCT00908349 Org: User:
Start: 06/30/09 End: 11/30/11 Due: 11/30/12

Open-Label and Single-Arm Study of MYOBLOC® in the Treatment of Troublesome Sialorrhea in Adults

Phase: N/A Priority: Normal
NCT ID: NCT02610868 Org: User:
Start: 10/31/15 End: 06/30/17 Due: 06/30/18

Evaluation of SPN-812 (Viloxazine Extended-release Capsule) in Preschool-age Children With ADHD

Phase: N/A Priority: Normal
NCT ID: NCT04781140 Org: User:
Start: 03/19/24 End: 12/31/25 Due: 12/31/26

Treatment of Impulsive Aggression (IA) in Adolescent With ADHD in Conjunction With Standard ADHD Treatment

Phase: N/A Priority: Normal
NCT ID: NCT03597503 Org: User:
Start: 07/31/18 End: 01/22/20 Due: 01/22/21

Treatment of Impulsive Aggression in Subjects With ADHD in Conjunction With Standard ADHD Treatment (CHIME 4)

Phase: N/A Priority: Normal
NCT ID: NCT02691182 Org: User:
Start: 04/30/16 End: 05/31/21 Due: 05/31/22